p. 3301 - 3302
(2007/10/03)(S,2E,4E)-8-(tert-butyldimethylsilyloxy)-6-(tert-butyldiphenylsilyloxy)-4-methylocta-2,4-dienenitrile
(S,2E,4E)-8-(tert-butyldimethylsilyloxy)-6-(tert-butyldiphenylsilyloxy)-4-methylocta-2,4-dien-1-amine
(E)-(S)-6-(tert-Butyl-dimethyl-silanyloxy)-4-(tert-butyl-diphenyl-silanyloxy)-2-methyl-hex-2-enal
(E,4R,5R)-5-((R)-1-((2,2,2-trichloroethoxy)carbonyl)pyrrolidine-2-carbonyloxy)-4,6-dimethylhept-2-enoic acid
(R)-Pyrrolidine-1,2-dicarboxylic acid 2-((E)-(1R,2R)-1-isopropyl-2-methyl-5-oxo-pent-3-enyl) ester 1-(2,2,2-trichloro-ethyl) ester
(R)-Pyrrolidine-1,2-dicarboxylic acid 2-{(E)-(1R,2R)-4-[(2E,4E)-(S)-6-(tert-butyl-diphenyl-silanyloxy)-4-methyl-8-oxo-octa-2,4-dienylcarbamoyl]-1-isopropyl-2-methyl-but-3-enyl} ester 1-(2,2,2-trichloro-ethyl) ester
(12E,17E,19E)-(7R,10R,11R,21S)-21-(tert-Butyl-diphenyl-silanyloxy)-10-isopropyl-11,19-dimethyl-9,26-dioxa-3,15,28-triaza-tricyclo[23.2.1.03,7]octacosa-1(27),12,17,19,25(28)-pentaene-2,8,14,23-tetraone
virginiamycin M2